Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Meribank Biotech Co's Total Assets for the quarter that ended in Dec. 2025 was NT$2,876.4 Mil.
Warning Sign:
If a company builds assets at 37.7% a year, faster than its revenue growth rate of 11% over the past 5 years, it means that the company may be getting less efficient.
During the past 12 months, Meribank Biotech Co's average Total Assets Growth Rate was 5.20% per year.
During the past 3 years, the average Total Assets Growth Rate was 60.60% per year.
During the past 5 years, the average Total Assets Growth Rate was 37.70% per year.
During the past 8 years, Meribank Biotech Co's highest 3-Year average Total Assets Growth Rate was 60.60%. The lowest was 1.50%. And the median was 12.40%.
Note:
The Net Income data used here is two times the semi-annual (Dec. 2025) data.
In the article Joining The Dark Side: Pirates, Spies and Short Sellers, James Montier reported that In their US sample covering the period 1968-2003, Cooper et al find that firms with low asset growth outperformed firms with high asset growth by an astounding 20% p.a. equally weighted. Even when controlling for market, size and style, low asset growth firms outperformed high asset growth firms by 13% p.a. Therefore a company with fast asset growth may underperform.
Total Assets is linked to total revenue through Asset Turnover.
Meribank Biotech Co's Asset Turnover for the quarter that ended in Dec. 2025 is
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Therefore, if a company grows its Total Assets faster than its Revenue, the Asset Turnover will decline. This might be a warning sign for the business.
Meribank Biotech Co Total Assets Related Terms
Meribank Biotech Co Total Assets Historical Data
* Premium members only.
The historical data trend for Meribank Biotech Co's Total Assets can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
From the capital sources of the assets, some of the assets are funded through shareholder's paid in capital and retained earnings of the business. Others are funded through borrowed money.
Meribank Biotech Co's Total Assets for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Meribank Biotech Co (ROCO:4724) has a Total Assets of NT$2,876.4 Mil as of Dec. 2025. The total amount of assets as recorded on a company's balance sheet. View historical data on Meribank Biotech Co and its competitors.
Is Meribank Biotech Co's Total Assets too high?
Meribank Biotech Co's current Total Assets is NT$2,876.4 Mil. Overall, Meribank Biotech Co has a GF Score™ of 40/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Meribank Biotech Co's Total Assets compare to VRTX and REGN?
Meribank Biotech Co's Total Assets of NT$2,876.4 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Assets for a Biotechnology company?
A good Total Assets depends on the Biotechnology industry context. However, Total Assets should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Assets mean?
A high Total Assets can signal that a stock is expensive relative to its fundamentals. The total amount of assets as recorded on a company's balance sheet. View historical data on Meribank Biotech Co and its competitors. Meribank Biotech Co's current Total Assets is NT$2,876.4 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Meribank Biotech Co stock overvalued right now?
Based on GuruFocus' analysis, Meribank Biotech Co (ROCO:4724) is currently considered Possible Value Trap. The stock's GF Value™ is NT$48.92, compared to a current price of NT$9.78 — trading 80% below its estimated fair value. The current Total Assets is NT$2,876.4 Mil. Meribank Biotech Co's overall GF Score™ is 40/100 with 6 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Assets calculated?
Total Assets is calculated from a company's financial statements. For Meribank Biotech Co (ROCO:4724), the current Total Assets is NT$2,876.4 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Meribank Biotech Co (ROCO:4724) Overvalued in 2026?
Based on GuruFocus' analysis, Meribank Biotech Co stock appears to be undervalued.
The current stock price of NT$9.78 is trading 80% below its estimated GF Value™ of NT$48.92.
GuruFocus considers Meribank Biotech Co to be Possible Value Trap.
Key valuation signals for ROCO:4724:
Total Assets: NT$2,876.4 Mil
GF Value™: NT$48.92 vs. price of NT$9.78 (80% below fair value)
No single metric tells the full story. See the ROCO:4724 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Meribank Biotech Co Ltd is engaged in Research and development and sales of new cell drugs and also Umbilical cord blood, placenta and umbilical cord mesenchymal stem cells processing, testing and cryopreservation.
40GF Score
Get the complete analysis for ROCO:4724
Total Assets is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:4724 has been successfully added to your 
